Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Blazesbon Aug 17, 2020 3:58pm

182 Views

Post# 31419538

RE:RE:Hiring Stern

afrodude89 wrote:
Hey blazesb, You are aware the drug is Naproxen attached to a hydrogen sulfide molecule, right? Not acetaminophen which is tylenol. All the best.

Afro, you need to get yourself up to speed on the phase 2 data fiasco. Acetaminophin 'significance' is, bizarrely, a very real thing.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading